Yahoo Web Search

    • Nicox Provides Fourth Quarter 2021 Business and Financial Highlights

      Morningstar· 1 day ago

      Mont Blanc Phase 3 clinical trial of NCX 470 in glaucoma progressing rapidly with recruitment now at 90% VYZULTA® and ZERVIATE® fourth quarter U.S. prescriptions increased by 39% and 129%, respectively, in 2021 vs. 2020 Net revenue of €3.5 million